Diagnostic and Prognostic Value of 18- Fluorodeoxyglucose Positron Emission Tomography in Adrenocortical Carcinoma: A Prospective Comparison with Computed Tomography
S. Leboulleux, C. Dromain, G. Bonniaud, A. Aupérin, B. Caillou, J. Lumbroso, R. Sigal, E. Baudin, and M. Schlumberger
Departments of Nuclear Medicine and Endocrine Tumors (S.L., J.L., E.B., M.S.), Radiology (C.D., R.S.), Medical Physics (G.B.), Epidemiology (A.A.), and Pathology (B.C.), Institut Gustave Roussy, 94805 Villejuif Cédex, France
Objective: Patients with adrenocortical cancer are submitted to mul- tiple imaging procedures for diagnosis of recurrence and staging. The aim of this prospective study was to evaluate the diagnostic and prognostic values of fluorodeoxyglucose (FDG) using a combined positron emission tomography and computed tomography (PET/CT) modality, compared with thoracoabdominopelvic computed tomogra- phy (TAP-CT).
Methods: Twenty-eight consecutive patients with adrenocortical cancer referred from November 2003 to December 2004 to the Institut Gustave Roussy were included. Mean time between PET/CT and TAP-CT was 16 d. Independent readers analyzed images of each modality. The gold standard was progression on follow-up TAP-CT or pathology.
Results: A total of 269 lesions in 57 organs were depicted in 22 patients. The sensitivities for the detection of distinct lesions and the
diagnosis of metastatic organs were 90 and 93% for PET/CT and 88 and 82% for TAP-CT, respectively. Twelve percent of the lesions were seen on PET/CT only and 10% on TAP-CT only. Eighteen percent of the metastatic organs were diagnosed with PET/CT only and 7% with TAP-CT only. Thirty-eight percent of the local relapses were seen only with PET/CT. PET/CT depicted three false-positive lesions. Treat- ment modalities were modified by PET/CT findings in five cases among which one was falsely positive. Tumor size and mitotic rate were significantly associated with FDG uptake. The intensity of FDG uptake (maximum standardized uptake value > 10) and the volume of FDG uptake (>150 ml) were significant prognostic factors for survival.
Conclusions: We show that FDG-PET/CT is complementary to TAP-CT and of special interest in the diagnosis of local relapses. (J Clin Endocrinol Metab 91: 920-925, 2006)
A DRENOCORTICAL CANCER (ACC) is a rare disease with a poor prognosis. In patients with initial com- plete surgery, the 2-yr recurrence rate ranges from 73 to 86% (1-4), and in those with metastatic disease, the 5-yr survival rate is less than 12% (1, 3, 5-8). Stage, completeness of initial resection, and high mitotic rate have been identified as prog- nostic factors of survival (4, 9-11). Functionality, age, and atypical mitosis had a deleterious impact on survival in some but not all studies (1, 3, 7, 9, 10, 12, 13).
Imaging modalities are performed in patients in complete remission for early diagnosis of recurrence because of the potential impact on survival and, in patients with metastatic disease for complete staging, evaluation of tumor progres- sion and response to therapy. For these reasons, patients with ACC are submitted to serial and extensive imaging evalua- tions, including thoracoabdominopelvic (TAP) computed to- mography (CT) and bone scintigraphy (BS). F-18 fluorode- oxyglucose (FDG) positron emission tomography (PET) is
Abbreviations: ACC, Adrenocortical cancer; BS, bone scintigraphy; 95% CI, 95% confidence interval; CT, computed tomography; FDG, F-18 fluorodeoxyglucose; PET, positron emission tomography; SUVmax, maximum standardized uptake value; TAP, thoracoabdominopelvic. JCEM is published monthly by The Endocrine Society (http://www. endo-society.org), the foremost professional society serving the en- docrine community.
now widely used as a diagnostic and prognostic tool for many cancers (14-19). It also appears to be useful for the diagnosis of malignancy of adrenal tumors (20-24). In a limited series of ACC patients, abnormal uptake of FDG was reported (25-27), but the exact role of PET in these patients has not yet been precisely defined.
The aims of this prospective study were therefore to eval- uate the diagnostic value of PET using an integrated PET/CT system in comparison with TAP-CT and to record modifi- cations of therapeutic options and to evaluate the prognostic value of PET on survival in patients with metastatic disease.
Patients and Methods
Patients
Twenty-eight consecutive patients with confirmed ACC referred to the Institut Gustave Roussy from November 2003 to December 2004 were enrolled in this study. TAP-CT was part of their usual work-up, to which PET/CT was added. BS was performed in three patients with bone pain. Mean time between PET/CT and TAP-CT was 16 d (range 0-44 d). Our institutional review board approved the study, and all patients gave written informed consent.
Imaging techniques
FDG PET. All imaging and data acquisitions were performed on an integrated PET/CT Biograph LSO system (Siemens Medical Solutions, Erlangen, Germany) using a single table serving for both the attenuation
correction CT and PET elements. PET/CT scanning was performed after an iv injection of 5 MBq/kg FDG, followed by a 60- to 120-min uptake phase. All patients had fasted for 6 h and capillary glycemia was normal in all patients (mean 5.0 mmol/liter; range 3.7-6.9). During the image acquisition, patients maintained their arms above their head and no specific breathing instructions were given.
The PET elements of the system are based on a full-ring tomograph (ECAT ACCEL, CPS Innovation, Knoxville, TN). Emission data were acquired for 4 min at each bed position from the top of the head to the midthigh. Three-dimensional mode was used for PET image acquisition. PET data were reconstructed on a 128 × 128 matrix, using an iterative algorithm (FORE and AWOSEM) with two iterations, eight subsets, and a 5-mm FWHM gaussian postfilter. Reconstruction data were acquired with a single slice spiral CT (Somatom Emotion, Siemens Medical So- lutions) without iv contrast agent. CT parameters were set to 80 mA and 110 kV, slice thickness of 5 mm, and pitch 1.5. CT data were recon- structed using filtered back projection with a smooth filter on a 512 X 512 matrix.
Maximum standardized uptake value (SUVmax) and FDG uptake tumor volume were determined in patients with abnormal FDG uptake. SUVmax was automatically extracted using e.Soft tools (Siemens Med- ical Solutions) dedicated to image analyses. The FDG uptake-related tumor volumes were estimated by a semiautomated image-intensity threshold volume calculated through a segmentation method, using an e.Soft-dedicated three-dimensional segmentation tool (Siemens Medical Solutions), as previously described (28, 29). Background level of activity was first determined in each organ. Contours of organs with abnormal FDG uptake were then manually drawn, excluding regions of physio- logical uptake. With the threshold technique, the total area of pixels with uptake value greater than a defined background to tumor ratio was summed to evaluate the FDG uptake-related tumor volume. The back- ground to tumor ratio chosen was 4 for lung parenchyma lesions and 2 otherwise. FDG uptake-related tumor volume is the sum of FDG uptake-related tumor volumes in each organ with abnormal FDG uptake.
TAP-CT scanning. TAP-CT with spiral CT was performed after oral administration of contrast medium and iv injection of iodinated contrast material with slice thickness varying from 5 to 10 mm.
BS. Bone scans were recorded 2-4 h after iv injection of 500-700 MBq 99mTc-hydroxymethylene diphosphonate, using a large field-of-view y-camera with a low-energy and high-resolution collimator.
Image quantitative analysis. Images of each modality were analyzed by two readers (S.L., C.D.), blindly and independently. An abnormal PET/CT was defined by nonphysiological FDG uptake in at least one site or by the detection of at least one site without FDG uptake detected on the attenuation correction CT. An abnormal TAP-CT was defined by the detection of at least one tumor site. The standard basis for diagnosis was either tumor progression on follow-up TAP-CT or tumor pathology in three cases. Numbers of involved organs and distinct lesions visualized by PET, PET/CT, and TAP-CT were recorded. Lung, mediastinum, thyroid, liver, pancreas, bones, testis, axillary lymph nodes, and local relapse were considered as distinct organs. Peritoneum and abdominal lymph nodes were considered as a single organ. When more than 15 lesions were depicted in a given organ, 16 were considered for the statistical analysis. PET, PET/CT, and TAP-CT results were compared per patient, per involved organ and per number of detected lesions. Modifications of therapeutic options based on PET/CT results were recorded.
Statistics
Data were analyzed using SAS statistical software (SAS Institute, Cary, NC). Sensitivities of PET, PET/CT, and TAP-CT and their 95% confidence intervals (95% CI) were calculated and compared using the McNemar test for matched proportions. Associations between FDG uptake (present or absent) and the following patient or tumor charac- teristics were analyzed: lesion size, plasmatic o,p’DDD levels (equal to, less than, or above 14 mg/liter in patients receiving treatment), hor- monal secretions (present or absent), high mitotic count (less than or above 20 mitoses per 50 high-power fields). A generalized estimating equation model for binomial data was used to take into account the
patient effect. Prognostic univariate analyses studied the following vari- ables: number of metastatic organs detected on PET/CT, SUVmax, and FDG volume uptake. The Kaplan-Meier method and the log-rank test were used for the estimation and comparison of survival curves. All reported P values are two-sided.
Results
Patients
Twenty-eight consecutive patients (eight males, 20 fe- males; mean age 49 yr, range 22-73 yr) were enrolled in this study. Nineteen patients were already known as metastatic and nine were considered in complete remission. Among the nine patients in complete remission, six had already under- gone reoperation for distant metastasis or local relapse. ACC diagnosis was confirmed by an experienced pathologist (B.C.) in 27 patients; in the remaining patient, the diagnosis of ACC was retained because of an adrenal mass with lung metastases, high cortisol, and undetectable ACTH plasma levels. High mitotic counts (more than 20 mitoses per 50 high-power fields) and atypical mitoses, assessed in 23 pa- tients, were present in five and eight patients, respectively. Mean time between initial surgery and PET/CT was 62 months (range 1-363; median 34 months). Overall, previous treatment modalities included surgery, systemic chemother- apy, liver chemoembolization, and external beam radiation therapy in 11, 13, three, and five patients, respectively. At the time of the study, nine patients had secreting ACC and 19 were under o,p’DDD treatment, among whom eight had o,p’DDD plasma levels above 14 mg/liter (mean 13.5, range 3.3-35.0 mg/liter).
The median follow-up after inclusion in the study was 8 months (range 0-16). Ten patients died from tumor progres- sion and one from treatment toxicity.
Imaging results
Per-patient analysis. Twenty-two patients had evidence of disease on the PET/CT or TAP-CT. PET/CT and TAP-CT were concordant in 25 patients, being abnormal on both imaging modalities in 20 patients and both normal in five patients. PET/CT and TAP-CT were discordant in three pa- tients. In one patient, PET/CT showed abnormal uptake in the axillary region that proved to be a fibrohistiocytoma at surgery. In one patient, PET/CT depicted a local relapse, whereas TAP-CT was normal. In the remaining patient, PET/CT was normal, whereas TAP-CT detected one liver lesion.
Per-organ analysis. The total number of metastatic organs was 57 (Table 1). PET/CT detected lesions in 53 organs and
| Detected with PET/CT | Not detected with PET/CT | |
|---|---|---|
| No. of metastatic organs | ||
| Detected with TAP-CT | 43 | 4 |
| Not detected with TAP-CT | 10 | na |
| No. of lesions | ||
| Detected with TAP-CT | 211 | 26 |
| Not detected with TAP-CT | 32 | na |
na, Not applicable.
TAP-CT in 47 organs. The sensitivity of PET/CT for the diagnosis of a metastatic organ was 93% (95% CI 83-98%) and the sensitivity of TAP-CT was 82% (95% CI 70-91%), the difference being not statistically significant (P = 0.11). With PET/CT, 10 as-yet-unknown metastatic organs were diag- nosed (two mediastinum, five local relapse, one peritoneum, one bone, and one testis), but four metastatic organs were missed (two liver, one mediastinum, and one local relapse) (Fig. 1). Organ involvement that had been detected only with PET/CT was confirmed by the evolution in seven cases and histologically in three cases. Of note, lung lesions were de- tected with PET/CT in two cases because lesions were seen on the correction attenuation CT scan, but they did not have FDG uptake.
Three false-positive lesions were found in three patients with PET/CT. All three were located in organs previously operated on for resection of metastases (axillary lymph node, thyroid, and pancreas, respectively). The proof that these FDG uptake foci were not related to ACC relapse was ob- tained histologically in the first patient and because of the absence of progression in the second case. Finally, in the third case, the lesion displayed a high level of FDG uptake and persisted on two consecutive PET/CT performed 3 months apart, but no other imaging modality was performed and follow-up was not available.
Per-lesion analysis. The total number of lesions detected was 269 in 22 patients (Table 1). PET/CT detected 243 lesions, and TAP-CT 237. The sensitivities of PET/CT for the diagnosis of lesions was 90% (95% CI 86-94%) and the sensitivity of TAP-CT was 88% (95% CI 84-92%), the difference being not statistically significant (P = 0.43). There were 44 non-FDG avid lesions. PET/CT and TAP/CT therefore detected more lesions than the PET alone could have (P < 0.001).
The detection of the lesions with PET/CT and TAP-CT according to the organs involved are reported in Table 2. In the 57 metastatic organs, the number of lesions detected with PET/CT was superior, identical to, or inferior to TAP-CT in 14 (25%), 33 (58%), and 10 (18%) cases, respectively. Thirty- eight percent of local relapses were seen only on PET/CT. Thirty-three, 30, and 24% of the liver, bone, and mediastinal lymph nodes lesions, respectively, were seen only on PET/ CT. Among the bone lesions seen only with PET/CT, there was one vertebral metastasis recurring after surgery (not seen on BS) and two distant bone metastases, not in the field of view of the TAP-CT (but visible on BS). Mediastinal lymph nodes were detected with PET/CT in only 24% of the cases and with TAP-CT in only 29% of the cases. Finally, 8 and 16% of the lung and abdominal lymph nodes and peritoneal me- tastases, respectively, were seen only with TAP-CT.
As already reported, PET/CT was falsely positive in three cases (axillary lymph node, thyroid, and pancreas).
Changes in therapeutic decisions
Because of PET/CT results, treatment modalities were modified in four patients (14%), leading to surgery (two cases), radiotherapy (one case), and systemic chemotherapy (one case). In addition, an axillary FDG uptake led to an axillary lymph node dissection in one case, with a definitive diagnosis of histiocytofibroma. A control PET/CT per-
A
B
C
formed 3 months later confirmed the disappearance of the uptake.
Predictive factors for FDG uptake (Table 3)
The size of the lesions (mean 19 mm, range 2-115; median 15) and the detection of FDG uptake were closely related (P <
| Involved organ (no.) | No. of lesions | Detected with | ||
|---|---|---|---|---|
| PET/CT and TAP-CT (%) | PET/CT only (%) | TAP-CT only (%) | ||
| Liver (10) | 43 | 26 (60) | 14 (33) | 3 (7) |
| Lung (17) | 169 | 151 (89) | 4 (2) | 14 (8) |
| Mediastinum (7) | 17 | 8 (47) | 4 (24) | 5 (29) |
| Local relapse (13) | 13 | 7 (54) | 5 (38) | 1 (8) |
| Abdominal lymph node and peritoneal carci- nomatosis (6) | 16 | 12 (75) | 1 (6) | 3 (19) |
| Bone (3) | 10 | 7 (70) | 3 (30) | 0 |
| Testis (1) | 1 | 0 | 1 (100) | 0 |
| Total | 269 | 211 (79) | 32 (12) | 26 (10) |
0.001). Lesions with a size of 5 mm or less showed FDG uptake in 17% (9 of 53); lesions 5-10 mm had uptake in 61% of cases (19 of 31); lesions larger than 10 mm had uptake in 90% (132 of 146) of cases. Of note, lung lesions accounted for all lesions 5 mm or less and for 71% of the lesions measuring 5-10 mm. Neither hormonal secretion status nor plasma o,p- ‘DDD levels correlated with FDG uptake (P = 0.47 and 0.8, respectively). In fact, FDG uptake was present in 124 of the 176 (77%) metastatic organs with plasma o,p’DDD levels above 14 mg/liter and in 73 of the 91 (80%) metastatic organs of patients with plasma OP’DDD levels less than 14 mg/liter, (P = 0.8). However, the only responding patient to o,p’DDD therapy had non-FDG avid lesions.
Among pathological criteria, a high mitotic count was significantly associated with FDG uptake, whereas the pres- ence of abnormal mitoses was not (P = 0.004 and P = 0.28, respectively).
Prognostic value of PET/CT
The prognostic factors for survival of 21 patients with at least one lesion are shown in Table 4 (one patient with a follow-up of less than 2 months was not included in the analysis). Univariate analysis showed the intensity of FDG uptake (SUVmax), and the FDG uptake volume was signif- icantly associated with survival (P = 0.03) (Fig. 2). The num- ber of metastatic organs diagnosed on PET/CT was not prog-
| No. of lesions | Lesions with FDG uptake (%) | P | |
|---|---|---|---|
| Size of the lesions (mm) | |||
| ≤5 | 53 | 9 (17) | |
| 5-10 | 31 | 19 (61) | <10-3 |
| >10 | 146 | 131 (90) | |
| o,p'DDD (mg/liter) | |||
| ≤14 | 176 | 123 (70) | 0.8 |
| >14 | 91 | 73 (80) | |
| Hormonal secretions | |||
| Present | 181 | 129 (71) | 0.47 |
| Absent | 86 | 68 (79) | |
| Mitotic count | |||
| ≤20 | 178 | 117 (66) | 0.004 |
| >20 | 34 | 32 (94) | |
| Atypical mitosis | |||
| Present | 137 | 89 (65) | 0.28 |
| Absent | 75 | 60 (80) | |
| Variables | n | 6-month survival (%) | P |
|---|---|---|---|
| No. of metastatic organs on PET/CT | |||
| ≤2 | 11 | 78 | |
| >2 | 10 | 51 | 0.47 |
| SUVmax | |||
| ≤10 | 8 | 100 | |
| >10 | 13 | 46 | 0.03 |
| FDG uptake volume | |||
| ≤150 ml | 10 | 86 | |
| >150 ml | 11 | 45 | 0.03 |
nostic for survival (P = 0.47). Given the number of patients in the analysis, no multivariate analysis was performed. There was, however, a statistically significant correlation between FDG uptake and FDG uptake volume (P = 0.009) and a trend in correlation of an FDG volume uptake of more than 150 ml and an SUVmax of more than 10 (P = 0.08).
Discussion
Treatment of ACC is an unresolved challenge for clini- cians. Even patients with initially complete surgery have a
A
1.0
0.9
0.8
0.7
0.6
0.5
SUV max ≤10
0.4
0.3
0.2
0.1
SUV max > 10
0.0
I
0
3
6
9
12 Months
At risk
-8
6
5
2
1
1
13
5
4
2
B
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
Volume ≤ 150 mL
0.2
Volume > 150mL
0.1
0.0
0
3
6
9
12
Months
At risk
-10
7
5
3
1
1
-11
4
4
1
high risk of relapse within the first 2 yr of follow-up (1-4). These relapses are exclusively local in 25-40% of the cases and can be associated with distant metastases or consist only in distant metastases otherwise. An early diagnosis is war- ranted because complete surgical resection may lead to longer survival (3,6). However, the detection of local relapse may be difficult with TAP-CT because of fibrosis due to previous surgery. In patients with metastatic disease, com- plete staging is often performed to assess tumoral progres- sion and treatment response.
We showed that PET/CT and TAP-CT have a similar sensitivity for the diagnosis of ACC metastases (90 and 88%, respectively). But they are complementary imaging modal- ities because 12 and 10% of the lesions were seen only by PET/CT or TAP-CT, respectively. The limitations of this study are the relatively low number of patients included and the absence of systematic pathologic characterization of all FDG uptake foci. This is because it was not possible to submit patients to multiple biopsies, except for those who under- went surgery for therapeutic reasons. Our study highlights the role of PET/CT for the diagnosis of local relapses. In fact, 38% (five of 13) of the local relapses were detected with PET/CT and not with TAP-CT. Furthermore, the diagnosis of five local relapses led to therapeutic changes in three of these five patients. FDG is, however, not a tumor-specific tracer, and an increased accumulation may be seen in a variety of benign entities, and notably in postoperative changes, yielding false-positive results. In fact, three patients had false-positive foci of FDG uptake in our study, one of which was due to postoperative changes and one to a benign entity; in the remaining patient, the cause could not be re- liably determined, but because of the high FDG uptake level and its persistence on a consecutive PET performed after 3 months, the lesion was most likely to be a relapse.
PET is limited by its spatial resolution. Its sensitivity for the diagnosis of lung cancer is known to be dependent on the tumor size (30). We found similar results in our study in that only 15% of the lesions with a size of 5 mm or less and 58% of the lesions with a size of 5-10 mm showed abnormal FDG uptake. However, because most small lesions are located in the lungs because of the miliary pattern of lung involvement, most of them can be detected with the CT correction atten- uation scan. PET/CT did not miss any diagnoses of meta- static lung; however, in three patients it detected fewer lung lesions than TAP-CT. CT parameters or the absence of spe- cific breathing instructions during attenuation correction CT may explain this difference. The other organs for which PET/CT detected fewer lesions than TAP-CT because of lesion size included liver (3), mediastinal lymph nodes (1), and peritoneal carcinomatosis (1). The above-cited technical reasons but also the absence of iodine contrast medium in- jection for the attenuation corrected CT acquisition can ex- plain this discrepancy. Injection of iodine contrast medium is not yet routinely used because it may modify the atten- uation correction coefficients (31-33). Therefore, given the low sensitivity of PET for the diagnosis of small lesions and the high frequency of lung lesions in ACC, patients with ACC should not be followed up by PET only. We believe that PET/CT cannot replace a diagnostic TAP-CT, as long as CT with attenuation correction is not as sensitive as a diagnostic
TAP-CT with contrast medium injection and CT diagnostic parameters. The use of PET/CT for treatment response eval- uation was not addressed in this study.
We showed that the intensity of FDG uptake is in ACC, as in other cancer types, related to the prognosis: 54% of the patients with a SUVmax above 10 died within 6 months after PET/CT examination, whereas none of the patients with a SUVmax lower than 10 died (14-19). Furthermore, we found a close relationship between FDG uptake and a high mitotic count on initial pathological specimens, which is a well- recognized independent prognostic factor for survival (4, 9-11). Not surprisingly, we also found that the FDG uptake volume, which is representative of tumor burden was related to survival, as has been shown for thyroid cancer (19). Fifty- five percent of the patients with an FDG uptake volume of more than 150 ml but only 14% of the patients with an FDG uptake volume of less than 150 ml died within 6 months after PET/CT examination. Ultimately, whether the intensity of FDG uptake and FDG uptake volume are independent prog- nostic factors for survival in patients with ACC has to be determined using multivariate analysis with a larger group of patients.
In conclusion, we have shown that PET/CT is comple- mentary to TAP-CT, and we have shown the importance of PET/CT in patients with ACC for the diagnosis of local relapse. Because of the high rate of small lesions without FDG uptake, patients with ACC should not be followed up by PET only. The intensity of FDG uptake in patients with ACC is related to survival. Whether it is an independent prognostic factor and whether it can be used for therapeutic manage- ment needs to be further studied.
Acknowledgments
Received July 12, 2005. Accepted December 9, 2005.
Address all correspondence and requests for reprints to: Martin Schlumberger, M.D., Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Rue Camille Desmoulins, 94805 Ville- juif Cedex, France. E-mail: schlumbg@igr.fr.
This work was supported by Programme Hospitalier de Recherche Clinique AOM 02-118.
The authors have no conflict of interest.
References
1. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C 2001 Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 25:891-897
2. Kendrick ML, Lloyd R, Erickson L, Farley DR, Grant CS, Thompson GB, Rowland C, Young Jr WF, van Heerden JA 2001 Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 136:543-549
3. Schulick RD, Brennan MF 1999 Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 6:719-726
4. Weiss LM, Medeiros LJ, Vickery Jr AL 1989 Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13: 202-206
5. Barzon L, Fallo F, Sonino N, Daniele O, Boscaro M 1997 Adrenocortical carcinoma: experience in 45 patients. Oncology 54:490-496
6. Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F, Favia G, Borrelli D, Boffi L, Capussotti L, Carbone G, Casaccia M, Cavallaro A, Del Gaudio A, Dettori G, Di Giovanni V, Mazziotti A, Marrano D, Masenti E, Miccoli P, Mosca F, Mussa A, Petronio R, Piat G, Marazano L, et al 1997 Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 122:1212-1218
7. Soreide JA, Brabrand K, Thoresen SO 1992 Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 16: 663-667; discussion 668
8. Grondal S, Cedermark B, Eriksson B, Grimelius L, Harach R, Kristoffersson A, Rastad J, Uden P, Akerstrom G 1990 Adrenocortical carcinoma. A retro- spective study of a rare tumor with a poor prognosis. Eur J Surg Oncol 16:500-506
9. Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, Cordon-Cardo C, Jaques DP, Brennan MF 2002 Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20:941-950
10. Tauchmanova L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A, Palmieri G, Marzano E, Salvatore M, Pettinato G, Lombardi G, Rossi R 2004 Adrenocortical carcinomas: twelve-year prospective experience. World J Surg 28:896-903
11. van Slooten H, Schaberg A, Smeenk D, Moolenaar AJ 1985 Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 55: 766-773
12. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, et al 1990 Clinical features of adre- nocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1195-1201
13. Henley DJ, van Heerden JA, Grant CS, Carney JA, Carpenter PC 1983 Ad- renal cortical carcinoma-a continuing challenge. Surgery 94:926-931
14. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V 2004 Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resec- tion. J Clin Oncol 22:3255-3260
15. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, Mortelmans LA, Demedts MG 1999 Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leu- ven Lung Cancer Group. J Clin Oncol 17:3201-3206
16. Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, Krohn K 2004 FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 130:1361-1367
17. Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrazzoli S 2003 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 7:953-959; discus- sion 959-960
18. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A 1999 Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 40:1241-1245
19. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ 2000 Prognostic value of [18F]fluoro- deoxyglucose positron emission tomographic scanning in patients with thy- roid cancer. J Clin Endocrinol Metab 85:1107-1113
20. Tenenbaum F, Groussin L, Foehrenbach H, Tissier F, Gouya H, Bertherat J, Dousset B, Legmann P, Richard B, Bertagna X 2004 18F-fluorodeoxyglucose
positron emission tomography as a diagnostic tool for malignancy of adre- nocortical tumours? Preliminary results in 13 consecutive patients. Eur J En- docrinol 150:789-792
21. Zettinig G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, Niederle B, Dudczak R, Kletter K 2004 Positron emission tomography im- aging of adrenal masses: (18)F-fluorodeoxyglucose and the 11ß-hydroxylase tracer (11)C-metomidate. Eur J Nucl Med Mol Imaging 31:1224-1230
22. Rao SK, Caride VJ, Ponn R, Giakovis E, Lee SH 2004 F-18 fluorodeoxyglucose positron emission tomography-positive benign adrenal cortical adenoma: im- aging features and pathologic correlation. Clin Nucl Med 29:300-302
23. Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Langsjo J, Salmi J, Valimaki M, Nagren K, Nuutila P 2004 Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med 45:972-979
24. Shimizu A, Oriuchi N, Tsushima Y, Higuchi T, Aoki J, Endo K 2003 High [18F]2-fluoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing’s syndrome. Ann Nucl Med 17:403-406
25. Becherer A, Vierhapper H, Potzi C, Karanikas G, Kurtaran A, Schmaljohann J, Staudenherz A, Dudczak R, Kletter K 2001 FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm 16:289-295
26. Kreissig R, Amthauer H, Krude H, Steinmueller P, Stroszczynski C, Hosten N, Grueters A, Felix R 2000 The use of FDG-PET and CT for the staging of adrenocortical carcinoma in children. Pediatr Radiol 30:306
27. Ahmed M, Al-Sugair A, Alarifi A, Almahfouz A, Al-Sobhi S 2003 Whole- body positron emission tomographic scanning in patients with adrenal cortical carcinoma: comparison with conventional imaging procedures. Clin Nucl Med 28:494-497
28. Zasadny KR, Kison PV, Francis IR, Wahl RL 1998 FDG-PET determination of metabolically active tumor volume and comparison with CT. Clin Positron Imaging 1:123-129
29. Erdi YE, Mawlawi O, Larson SM, Imbriaco M, Yeung H, Finn R, Humm JL 1997 Segmentation of lung lesion volume by adaptive positron emission to- mography image thresholding. Cancer 80:2505-2509
30. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, Karis J, Hubner K, Delbeke D, Heiberg EV, Patz EF, Coleman RE 1998 Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 16:1075-1084
31. Antoch G, Freudenberg LS, Egelhof T, Stattaus J, Jentzen W, Debatin JF, Bockisch A 2002 Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 43:1339-1342
32. Beyer T, Antoch G, Bockisch A, Stattaus J 2005 Optimized intravenous con- trast administration for diagnostic whole-body 18F-FDG PET/CT. J Nucl Med 46:429-435
33. Yau YY, Chan WS, Tam YM, Vernon P, Wong S, Coel M, Chu SK 2005 Application of intravenous contrast in PET/CT: does it really introduce sig- nificant attenuation correction error? J Nucl Med 46:283-291
JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.